Linezolid
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
Linezolid: Drug Repurposing Evaluation — Awaiting Prediction Data
One-Sentence Summary
Linezolid (DB00601) is an oxazolidinone-class antibiotic used for serious gram-positive bacterial infections, including MRSA and VRE. This Evidence Pack returned no TxGNN predicted indications, and two critical data gaps — mechanism of action and safety warnings — are unresolved. A complete repurposing evaluation cannot be conducted at this time; the decision is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | No prediction returned |
| TxGNN Prediction Score | — |
| Evidence Level | N/A |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Taiwan Market Information
Linezolid currently holds zero authorizations in Taiwan and is not marketed. No license records were found in the TFDA database.
A successful TFDA package insert query was logged (2026-03-29), but the retrieved content has not yet been parsed into structured fields. Pending manual review of that document may unlock safety and indication data.
Safety Considerations
Please refer to the package insert for safety information. The following data remain unresolved:
- Key Warnings: Not yet extracted from TFDA package insert
- Contraindications: Not yet extracted from TFDA package insert
- Drug Interactions: No records found in the DDI database
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model returned no predicted indications for Linezolid, making it impossible to evaluate any repurposing hypothesis. Two upstream data gaps — a Blocking-severity gap in TFDA safety information and a High-severity gap in mechanism of action — further prevent risk assessment even if a prediction were available.
To proceed, the following is needed:
- [Blocking] Parse the TFDA package insert PDF already retrieved (2026-03-29) to extract key warnings and contraindications
- [High] Query DrugBank API for Linezolid (DB00601) mechanism of action (MOA)
- [Required] Re-run TxGNN prediction pipeline for DB00601 to generate indication candidates
- [Supplementary] Expand DDI database search or consult an alternative interaction source (e.g., Lexicomp, Micromedex)
Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.